BlackRock’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-7,102,626
| Closed | -$29.8M | – | 5727 |
|
|
2023
Q1 | $29.8M | Buy |
7,102,626
+42,307
| +0.6% | +$220K | ﹤0.01% | 2763 |
|
|
2022
Q4 | $42.4M | Buy |
7,060,319
+461,546
| +7% | +$2.52M | ﹤0.01% | 2578 |
|
|
2022
Q3 | $38.4M | Buy |
6,598,773
+707,804
| +12% | +$4.41M | ﹤0.01% | 2654 |
|
|
2022
Q2 | $35.2M | Buy |
5,890,969
+4,099,276
| +229% | +$21M | ﹤0.01% | 2731 |
|
|
2022
Q1 | $8.37M | Sell |
1,791,693
-7,137
| -0.4% | -$21.3K | ﹤0.01% | 3670 |
|
|
2021
Q4 | $4.46M | Buy |
1,798,830
+903,439
| +101% | +$2.21M | ﹤0.01% | 4041 |
|
|
2021
Q3 | $2.64M | Sell |
895,391
-1,660
| -0.2% | -$4.52K | ﹤0.01% | 4203 |
|
|
2021
Q2 | $2.24M | Sell |
897,051
-33,559
| -4% | -$80.5K | ﹤0.01% | 4221 |
|
|
2021
Q1 | $2.71M | Buy |
930,610
+20,573
| +2% | +$67.2K | ﹤0.01% | 4188 |
|
|
2020
Q4 | $2.93M | Sell |
910,037
-18,242
| -2% | -$60.7K | ﹤0.01% | 3907 |
|
|
2020
Q3 | $2M | Sell |
928,279
-3,187
| -0.3% | -$4.07K | ﹤0.01% | 3899 |
|
|
2020
Q2 | $1.08M | Buy |
931,466
+178,150
| +24% | +$188K | ﹤0.01% | 4023 |
|
|
2020
Q1 | $693K | Buy |
753,316
+141,810
| +23% | +$163K | ﹤0.01% | 3980 |
|
|
2019
Q4 | $966K | Buy |
611,506
+270,555
| +79% | +$256K | ﹤0.01% | 4004 |
|
|
2019
Q3 | $286K | Buy |
340,951
+826
| +0.2% | +$630 | ﹤0.01% | 4266 |
|
|
2019
Q2 | $292K | Sell |
340,125
-2,454,590
| -88% | -$2.27M | ﹤0.01% | 4290 |
|
|
2019
Q1 | $2.71M | Sell |
2,794,715
-99,141
| -3% | -$104K | ﹤0.01% | 3601 |
|
|
2018
Q4 | $2.12M | Buy |
2,893,856
+9,495
| +0.3% | +$15.6K | ﹤0.01% | 3643 |
|
|
2018
Q3 | $6.23M | Buy |
2,884,361
+81,179
| +3% | +$201K | ﹤0.01% | 3430 |
|
|
2018
Q2 | $14M | Buy |
2,803,182
+2,369,398
| +546% | +$10.4M | ﹤0.01% | 3068 |
|
|
2018
Q1 | $1.69M | Buy |
433,784
+18,666
| +4% | +$65.6K | ﹤0.01% | 3723 |
|
|
2017
Q4 | $1.11M | Buy |
415,118
+7,586
| +2% | +$22.2K | ﹤0.01% | 3874 |
|
|
2017
Q3 | $1.3M | Buy |
407,532
+20,763
| +5% | +$69.3K | ﹤0.01% | 3829 |
|
|
2017
Q2 | $1.28M | Buy |
386,769
+32,069
| +9% | +$125K | ﹤0.01% | 3787 |
|
|
2017
Q1 | $1.49M | Buy |
+354,700
| New | +$1.64M | ﹤0.01% | 3734 |
|
|
2016
Q2 | – | Sell |
-1,431
| Closed | -$8K | – | 3942 |
|
|
2016
Q1 | $8K | Buy |
1,431
+1,099
| +331% | +$8.78K | ﹤0.01% | 3259 |
|
|
2015
Q4 | $4K | Hold |
332
| – | – | ﹤0.01% | 3238 |
|
|
2015
Q3 | $5K | Hold |
332
| – | – | ﹤0.01% | 3063 |
|
|
2015
Q2 | $6K | Sell |
332
-77
| -19% | -$1.49K | ﹤0.01% | 3113 |
|
|
2015
Q1 | $7K | Hold |
409
| – | – | ﹤0.01% | 2958 |
|
|
2014
Q4 | $10K | Buy |
409
+63
| +18% | +$1.46K | ﹤0.01% | 2814 |
|
|
2014
Q3 | $8K | Hold |
346
| – | – | ﹤0.01% | 2910 |
|
|
2014
Q2 | $10K | Buy |
346
+1
| +0.3% | +$30 | ﹤0.01% | 2833 |
|
|
2014
Q1 | $12K | Hold |
345
| – | – | ﹤0.01% | 2645 |
|
|
2013
Q4 | $7K | Buy |
345
+90
| +35% | +$1.64K | ﹤0.01% | 2973 |
|
|
2013
Q3 | $4K | Buy |
+255
| New | +$2.96K | ﹤0.01% | 3060 |
|
Other funds holding CTIC
BlackRock's CTIC Position: Q2 2023 in Review
BlackRock sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 7,102,626 shares — an estimated $29.8M sold.
BlackRock first reported a position in CTIC in Q3 2013 and held it in 36 quarters. The position peaked at $42.4M in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.
- BlackRock reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
- BlackRock sold 7,102,626 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $29.8M.
- BlackRock first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2013 and held it in 36 quarters.
- BlackRock's CTI BioPharma Corp. (DE) Common Stock position peaked at $42.4M in Q4 2022.
- 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.
Based on BlackRock's 13F filing for Q2 2023, filed 11 Aug 2023.